Loading
Life sciences · Journal article
Cancers · November 4, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Background: Systemic treatment choices after failure of standard therapy are limited for malignant mesothelioma. Oral vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) have been incorporated into salvage treatment strategies, but real-world evidence regarding their effectiveness and safety remains scarce. Methods: We retrospectively analyzed a single-center cohort comprising patients with pathologically confirmed malignant mesothelioma treated at Cancer Hospital, Chinese Academy of Medical Sciences/National Cancer Center between 1 April 2017 and 16 March 2023. Patients with unresectable disease who received a VEGFR-TKI-containing regimen and had sufficient clinical follow-up for outcome assessment were included. Progression-free survival (PFS) served as the primary endpoint. Objective response rate (ORR), disease control rate (DCR), overall survival (OS) from VEGFR-TKI initiation, and recorded adverse events were included as secondary endpoints. Results: The cohort comprised 48 patients, with a median follow-up of 24.0 months. The Kaplan–Meier estimated median PFS was 4.8 months (95% CI, 2.9–8.8), and median OS from VEGFR-TKI initiation was 17.9 months (95% CI, 13.5–not estimable). Among 39 response-evaluable patients, 6 achieved partial response, 20 had stable disease, and 13 had progressive disease as their best overall response, yielding an ORR of 15.4% and a DCR of 66.7%. Two patients remained progression-free for more than 24 months. Grade 3 adverse events in the records included hematuria, hypertension, and nausea/vomiting; no grade 4 or grade 5 adverse event was documented. Conclusions: VEGFR-TKI-containing therapy was associated with clinically relevant disease control in unresectable malignant mesothelioma, with durable benefit observed in a small subset of patients. These observations warrant further evaluation of VEGFR-TKI-based salvage strategies in larger multicenter cohorts.